LifeStance Health Group Inc. Common Stock vs TransMedics Group Inc — how do they compare? LifeStance Health Group Inc. Common Stock trades at $12.42 (market cap $4.58B), while TransMedics Group Inc trades at $78.19 (market cap $2.74B). The key difference: LifeStance Health Group Inc. Common Stock is the larger of the two by market cap, and LifeStance Health Group Inc. Common Stock is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LifeStance Health Group Inc. Common Stock for 1 Days and TransMedics Group Inc for 24 Days on average.
| LFST | TMDX | |
|---|---|---|
Market Cap | $4.58B | $2.74B |
Volume | 2,356,698 | 949,331 |
Sector | Health | Health |
52-Week High | $13.38 | $150.42 |
52-Week Low | $4.81 | $61.99 |
Typical Hold Time | 1 Days | 24 Days |
Enterprise Value | $4.82B | $3.13B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
LifeStance Health provides outpatient mental healthcare, including therapy, psychiatry, and medication management services.
Read more on LFST →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →